# Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics

> **NCT01939587** · PHASE2 · COMPLETED · sponsor: **Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau** · enrollment: 21 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** PBF-680 5 mg
- **DRUG:** PBF-680 20 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01939587
- **Lead sponsor:** Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2016-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01939587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01939587, "Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01939587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*